TWi Biotechnology, Inc. announced that it is currently seeking participants for a Phase 1 clinical trial of a topical gel called tofacitinib for the treatment of granuloma annulare (GA). The TWiB team and collaborating physicians invite eligible individuals to participate in this study at Yale University Hospital.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.2 TWD | +0.76% | +4.76% | -5.71% |
09/04 | TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | TWi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-5.71% | 3.57Cr | |
+51.85% | 5.79TCr | |
+41.42% | 4.03TCr | |
-5.25% | 3.99TCr | |
-5.16% | 2.85TCr | |
+12.79% | 2.64TCr | |
-20.18% | 1.93TCr | |
+30.88% | 1.24TCr | |
+0.61% | 1.22TCr | |
+25.06% | 1.22TCr |
- Stock Market
- Equities
- 6610 Stock
- News TWi Biotechnology, Inc.
- TWi Biotechnology, Inc. Exploring Promising Treatment for Granuloma Annulare (Ga)